Report Keyword:

China In-Vitro Diagnosis Industry Indepth Research and Investment Strategy Planning Report, 2013-2017

China In-Vitro Diagnosis Industry Indepth Research and Investment Strategy Planning Report, 2013-2017

Last Update:2014-05-25

Form of services:Book + (pdf or doc file) + CD

Send method:EMS 2-3 days for delivery

English Service:+86 0755 33220413

Chinese Service:+86 800-8306390 800-8306395

E-mail:service.en@qianzhan.com

Report price:$7900   Print: $7800   CD: $7800

Online Consultation
Special statement:
Recently we find there are some sites steal report contents from Qianzhan.com who put those contents on their sites for sale by making a little changes about the contents or remaining the same which deceives buyers(e.g. unable to get full or correct reports, or main body differs from contents that announced on sites).Therefore, we recommend paying a visit to Qianzhan personally or by your friends, and make payment after confirmation. Special statement: Qianzhan is the only and right holder of all the research reports, and has never used a third party to sell any reports, please be aware of the trademark " " when purchasing. Qianzhan is the largest and strongest consultancy, who owns the greatest number of researchers. Here followed "Nine standards of companies' identificatios"。

This table of content is original, without written permission of Qianzhan, any unit or individual shall not use, copy, or transfer the reports.

Preface

Table of Content

With the development of modern laboratory medicine, in-vitro diagnosis industry (IVD industry) comes into being. In reverse, it promotes the rapid development of laboratory, preclinical medicine and other disciplines. At present, 2/3 medical decisions have been made on the basis of diagnostic message in the world, while the diagnostic income occupies only 1% of the total medical expense. The further improvement of diagnostic technologies to disease prevention, diagnosis and treatment has positive meaning, and the diagnostic reagent industry has vast space for development.

IVD industry is always one of key supporting industries in domestic. Since 2005, the State Council, the National Development and Reform Committee, the Ministry of Science and Technology issued many policies, which play a positive role in promoting the development of diagnostic reagent, diagnostic equipment, and enzymic preparations related to diagnosis, and which also strengthen the competitiveness of domestic diagnostic reagent enterprises.

Since 2006, the domestic IVD industry has shown the rapid growth of the annual increase rate of around 15%. According to statistics, the market size of China IVD industry in 2008 reached 9.5 billion Yuan, and it increased to 12.2 billion Yuan in 2010. It’s predicted the market size of IVD industry will maintain at an increase rate of around 15%. By 2015, the market size of China IVD industry is anticipated to exceed 30 billion Yuan, which is expected to the third market in the world, with an average increase rate between 15% and 20%.

In recent years, the high-speed growth and high profit characteristic of IVD industry attract a group of enterprises rushing into this field. The gross profit rate of national enterprises in this industry is around 50%, such as Biosino Bio-technology and Science Inc., which listed in Hong Kong, Shanghai Kehua Bio-Engineering Co., Ltd. and Da An Gene Co., Ltd., which listed in Guangzhou, and Shenzhen), which listed in NYSE.

The local leading enterprises both accelerate to implement the diversification development strategies, and keep investing in IVD projects. At the end of February 2012, BioSino Bio-technology and Science Inc. and Abbott, a leading diversification healthcare company, announced that they had signed the sales and delivery cooperative projects together. On January 16th, the DA An Gene, a leading high-tech enterprise oriented in molecular diagnostic techniques, announced to invest 14.88 million Yuan, to sign cooperative contract with Life Technologies, whose headquarter locates in California, USA, for establishing early diagnosis on cancer, infectious disease and inherited disease.

Overall, China IVD industry is now in the early development phase. The industry has huge space for development. There are more than 20,000 hospitals, 530 blood stations, the ever-changing health examination centers and the emerging independent clinic labs in China, which provide huge maker demand for IVD industry. From the perspective of customers, the goal market of IVD reagents has shifted from focusing on hospital to the equal development of hospital, third party healthcare examinations centers and families. With the increasing prevention and precaution awareness of residents, and with the increase of high and middle-income earners and long-term supervision groups, the home diagnosis reagent will show its explosive growth.

In addition, with the deepening of new healthcare reform and with growing attention to people’s livelihood, the primary hospitals bring huge growth for IVD industry. The State invests in primary health system with as high as 100 billion Yuan, and the most beneficial industry segments is the common products for biochemical reagents. All in all, many industry segments of diagnosis reagents all have investment opportunities, while home diagnosis reagents will be a focus in the future.

Qianzhan Business Information Co., Ltd. Industry Research Center
Research Team of IVD Industry


China In-Vitro Diagnosis Industry Report" related reports »

Purchase Mode:

1. English Service:  +86 0755 33220413

2. Chinese Service:  +86 8008306390 8008306395

3. Mail Order:  service.en@qianzhan.com

4. Online Order:  Click "Order Now" button on this page

5. Purchase On-site:  19F Block A, First World Plaza, Hongli West Rd, Futian District, Shenzhen China

Warm tips:
  • 1. Please be aware of " Qianzhan " trademark, qianzhan has never used any third to sell reports, please make a phone call and purchase it directly.
  • 2. You are warmly welcome to visit Qianzhan, and close transaction after confirmation.
Industry Research
·Energy and Environment»
New Energy Natural Gas Energy Conservation Water Resources Coal Electricity Others
·Recreation and Sports»
Education Advertisement Film and Television Publication Packing and Printing Sports Resort Hotel Catering Internet Animation Others Media
·Financial Services»
Banking Insurance Securities Leasing Credit Others
·Transport Logistics and Supporting»
Water Transport Airport Road Transport Logistic Distribution Vehicle and Fittings Post-Market Others
·Medical and Health»
Medical Device Biomedicine Medical Institution Healthcare and Nursing Medicine and Pharmacy Others
·Retail or FMCG»
Retail Commercial Trade Food Beverage Dairy Product Seasoning Wine and Tobacco Cosmetics Cleaning Product Daily Necessities Others
·Real Estate and Construction»
Real Estate Real Estate Intermediary Public Safety Construction Engineering Survey and Design Building Materials Housing Accomodation Others
·Mechanical Manufacturing»
Precision Instrument Transport Instrument Electricity Supporting Equipment Special Equipment General Equipment Others
·New Chemical Material»
Ink and Pigment Coating Chemical Fibres Synthetic Fibres Chemicals Industrial Chemicals Rubber Plastics Basic Chemicals Others
·Light Textile and Clothing»
Luxury Jewelry Leather Raw Materials Shoes and Hats Clothing Textile Others
·Household Appliance and IT»
White Goods Optic Instrument Electrical Component Semiconductor Brown Goods Small Appliances Communication IT Consumer Electronics Others
·Minerals and Metallurgy»
Metal Product Metallurgy Non-Ferrous Metal Steel Mining Industry Others
Copyright Notice

1. The copyright of this report is reserved by Qianzhan Business Information Co., Ltd. (Industry Research Institute of Qianzhan), the shipment and post-sale service is handled by the issue department of Qianzhan Business Information Co., Ltd. (Industry Research Institute of Qianzhan). The only copyright of all research report products of our company is reserved; we did not authorize any third party sales agent, if you are to purchase our report, please contact our customer service directly.

2. A limited of customers are offered with our reports with compensation; those reports are only for internal usage and are only for researching and analyzing purposes. We will not be responsible for any misunderstanding or legal issues caused by external usage or references with the report.

More>>
Beginner's Guide
Order Reference
Delivery & Payment
Sale protection
Service Hotline
  • Order Hotline:+86 800-830-6390
  • Customer service:
    +86 800-830-6395
    +86 400-068-7188